140 related articles for article (PubMed ID: 29921827)
1. Differential Expression and Pathway Analysis in Drug-Resistant Triple-Negative Breast Cancer Cell Lines Using RNASeq Analysis.
Shaheen S; Fawaz F; Shah S; Büsselberg D
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29921827
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
Yellapu NK; Ly T; Sardiu ME; Pei D; Welch DR; Thompson JA; Koestler DC
BMC Cancer; 2022 Jun; 22(1):627. PubMed ID: 35672711
[TBL] [Abstract][Full Text] [Related]
3. CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
Han XL; Du J; Zheng YD; Dai JJ; Lin SW; Zhang BY; Zhong FB; Lin ZG; Jiang SQ; Wei W; Fang ZY
Biomed Res Int; 2021; 2021():5089371. PubMed ID: 33959656
[TBL] [Abstract][Full Text] [Related]
4. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
5. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
He J; Yang J; Chen W; Wu H; Yuan Z; Wang K; Li G; Sun J; Yu L
PLoS One; 2015; 10(6):e0129842. PubMed ID: 26103053
[TBL] [Abstract][Full Text] [Related]
6. Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis.
Liu Q; Song X; Liu Z; Yu Z
Technol Cancer Res Treat; 2021; 20():15330338211019506. PubMed ID: 34184566
[TBL] [Abstract][Full Text] [Related]
7. Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis.
Dong P; Yu B; Pan L; Tian X; Liu F
Biomed Res Int; 2018; 2018():2760918. PubMed ID: 30175120
[TBL] [Abstract][Full Text] [Related]
8. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
Shu S; Wu HJ; Ge JY; Zeid R; Harris IS; Jovanović B; Murphy K; Wang B; Qiu X; Endress JE; Reyes J; Lim K; Font-Tello A; Syamala S; Xiao T; Reddy Chilamakuri CS; Papachristou EK; D'Santos C; Anand J; Hinohara K; Li W; McDonald TO; Luoma A; Modiste RJ; Nguyen QD; Michel B; Cejas P; Kadoch C; Jaffe JD; Wucherpfennig KW; Qi J; Liu XS; Long H; Brown M; Carroll JS; Brugge JS; Bradner J; Michor F; Polyak K
Mol Cell; 2020 Jun; 78(6):1096-1113.e8. PubMed ID: 32416067
[TBL] [Abstract][Full Text] [Related]
10. Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
Lanceta L; Lypova N; O'Neill C; Li X; Rouchka E; Chesney J; Imbert-Fernandez Y
Breast Cancer Res Treat; 2021 Apr; 186(3):677-686. PubMed ID: 33599863
[TBL] [Abstract][Full Text] [Related]
11. Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cells.
Kong X; Ding X; Yang Q
Int J Oncol; 2015 May; 46(5):2047-56. PubMed ID: 25826742
[TBL] [Abstract][Full Text] [Related]
12. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
13. RNA-seq based transcriptome analysis of EHMT2 functions in breast cancer.
Kim K; Ryu TY; Ryu JW; Han TS; Jung CR; Son MY; Kim DS; Cho HS
Biochem Biophys Res Commun; 2020 Apr; 524(3):672-676. PubMed ID: 32033749
[TBL] [Abstract][Full Text] [Related]
14. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
[TBL] [Abstract][Full Text] [Related]
16. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
18. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
Zhao H; Li D; Zhang B; Qi Y; Diao Y; Zhen Y; Shu X
Molecules; 2017 Dec; 22(12):. PubMed ID: 29261144
[TBL] [Abstract][Full Text] [Related]
19. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of the potential roles of miRNA‑mRNA networks in triple negative breast cancer.
Zhu H; Dai M; Chen X; Chen X; Qin S; Dai S
Mol Med Rep; 2017 Aug; 16(2):1139-1146. PubMed ID: 28627677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]